Related Experiment Video
Updated: Jun 21, 2026
10:16
In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease
Published on: December 20, 2017
Management of neuronopathic Gaucher disease: revised recommendations
A Vellodi1, A Tylki-Szymanska2, E H Davies3
1Metabolic Unit, Great Ormond Street Hospital for Children NHS Trust, Great Ormond Street, WC1N 3JH, London, UK. VelloA@gosh.nhs.uk.
Journal of Inherited Metabolic Disease
|August 6, 2009
Summary
High-dose enzyme replacement therapy (ERT) for neuronopathic Gaucher disease may not stabilize neurological symptoms. Evidence suggests ERT is more effective for severe visceral manifestations than for neurological impact.
Area of Science:
- Biochemistry
- Genetics
- Neurology
Background:
- Gaucher disease is a rare genetic disorder.
- Neuronopathic forms present significant neurological challenges.
- Current management guidelines require updates regarding therapy efficacy.
Purpose of the Study:
- To revise existing guidelines for neuronopathic Gaucher disease management.
- To evaluate the efficacy of high-dose enzyme replacement therapy (ERT) in stabilizing neurological disease.
- To determine the role of high-dose ERT in treating visceral manifestations.
Main Methods:
- Systematic analysis of published evidence on high-dose ERT (120 IU/kg every 2 weeks).
- Review of studies focusing on neurological and visceral outcomes in neuronopathic Gaucher disease.
- Assessment of ERT's impact on disease stabilization.
Main Results:
- Published evidence does not support the use of high-dose ERT for stabilizing neurological disease.
- High-dose ERT may be necessary for managing severe visceral aspects of Gaucher disease.
Conclusions:
- The role of high-dose ERT in neurological stabilization is not supported by current evidence.
- High-dose ERT remains a potential treatment for severe visceral Gaucher disease.
- Guideline revision is necessary, particularly concerning neurological management.
Related Concept Videos
01:22Lysosomal Hydrolases
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:20Myasthenia Gravis: Overview and Treatment
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:29Chronic Pancreatitis II: Collaborative Care
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
01:24Cystic Fibrosis: Management
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic sinusitis...
Sinus disease and chronic sinusitis...